How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Reduction in Thyroid-Stimulating Hormone Correlated with Improved Inflammation Markers in Chinese Patients with Morbid Obesity Undergoing Laparoscopic Sleeve Gastrectomy. (PubMed)

changes after laparoscopic sleeve gastrectomy (LSG) in Chinese patients with morbid obesity.Eighty-eight patients with morbid obesity (56.8% female; age 30.9 ± 9.5 years; BMI 39.9 ± 5.7 kg/m2) submitted to LSG were selected. Patients were subdivided into euthyroid group and subclinical hypothyroidism (SH) group. Thyroid-stimulating hormone (TSH), free thyroxine (FT4), inflammatory markers, and related metabolic indexes were analyzed pre- and 12 months post-LSG.SH patients presented significantly

2019 Obesity Surgery

82. Patients Treated for Hyperthyroidism Are at Increased Risk of Becoming Obese: Findings from a Large Prospective Secondary Care Cohort. (PubMed)

of obesity in male (odds ratio = 1.7 [95% confidence interval 1.3-2.2], p < 0.001) and female (1.3, 1.2-1.5, p < 0.001) patients with hyperthyroidism compared with the background population. Treatment with 131I was associated with additional weight gain (0.6 kg, 0.4-0.8, p < 0.001), compared with ATD treatment alone. More weight gain was seen if serum thyrotropin (TSH) was markedly increased (TSH >10 mIU/L; 0.5 kg, 0.3-0.7, p < 0.001) or free thyroxine (fT4) was reduced (fT4 ≤ 10 pmol/L (0.8 ng/dL); 0.3 (...) if weight gain seen following treatment for hyperthyroidism represents replenishment of premorbid weight or "overshoot" beyond expected regain and, if there is excessive weight gain, whether this is associated with the applied treatment modality. Methods: We calculated the risk of becoming obese (body mass index [BMI] >30 kg/m2) following treatment for hyperthyroidism by comparing BMI of 1373 patients with overt hyperthyroidism seen in a secondary care setting with the age- and sex-matched background

2019 Thyroid

83. Long term follow up of survivors of childhood cancer

, 2008 edition (www.sign.ac.uk/guidelines/fulltext/50/index. html). More information on accreditation can be viewed at www.evidence.nhs.uk Healthcare Improvement Scotland (HIS) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion/belief and sexual orientation. SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality (...) in every detail at the time of publication. However, in the event of errors or omissions corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Long term follow up of survivors of childhood cancer A national clinical guideline March

2013 SIGN

84. Pre-conception - advice and management

associated with first trimester maternal exposure to fluoxetine. Issued in June 2011. September 2010 — minor update. Text amended to include recommendations from the National Institute for Health and Care Excellence (NICE) public health guidance 27 about preparing for pregnancy for women with a body mass index (BMI) of 30 kg/m 2 or more. Issued September 2010. January 2009 — minor update to clarify the advice for folic acid supplementation in women with sickle-cell anaemia and thalassaemia. Issued (...) information about how to assess and manage individual components is provided by following the hyperlinks. Assess the following in a woman who is planning to become pregnant: Plans for timing of pregnancy. Previous obstetric history. Dietary habits and body mass index. Use of folic acid and dose taken in relation to her risk of neural tube defect . Cervical smear status. Smoking status. Amount of alcohol consumed. Use of illicit drugs and risk of hepatitis B. Immunity to rubella and chickenpox. Concerns

2017 NICE Clinical Knowledge Summaries

85. Longer sleep is associated with lower BMI and favorable metabolic profiles in UK adults: Findings from the National Diet and Nutrition Survey. (PubMed)

cholesterol (0.03 mmol/L per hour, 95% CI 0.00 to 0.05, p = 0.03). Sleep duration tended to be positively associated with free thyroxine levels and negatively associated with HbA1c and CRP (p = 0.09 to 0.10). Contrary to our hypothesis, sleep duration was not associated with any dietary measures (p ≥ 0.14). Together, our findings show that short-sleeping UK adults are more likely to have obesity, a disease with many comorbidities. (...) -sensitivity C-reactive protein (CRP) were measured in a subset of participants. We used regression analyses to explore associations between sleep duration and outcomes. After adjustment for age, ethnicity, sex, smoking, and socioeconomic status, sleep duration was negatively associated with body mass index (-0.46 kg/m2 per hour, 95% CI -0.69 to -0.24 kg/m2, p < 0.001) and waist circumference (-0.9 cm per hour, 95% CI -1.5 to -0.3cm, p = 0.004), and positively associated with high-density lipoprotein

Full Text available with Trip Pro

2017 PLoS ONE

86. Richard Lehman’s journal review—10 April 2017

attached. If you measure these, and the amount of thyroid stimulating hormone (TSH or thyrotropin), you have a nice little trio of biochemical parameters to play with and for people to attach symptoms to. in people of mean age 74 with an elevated serum thyrotropin level and a serum free thyroxine level within the reference range. This has come to be called “subclinical hypothyroidism.” The treated group received levothyroxine at a dose sufficient to bring their thyrotropin levels into the “normal (...) or in the graphics. But the message is clear: not all the increase in thyroid cancer in the US is an artefact of overdiagnosis. Ann Intern Med 4 Apr 2017 Vol Weight history counts Back to weight variation. It’s not your current body mass index that relates most closely to mortality, but your highest ever BMI. This applies to you directly if you are a male doctor or a female nurse in the US, as these . It applies even more if you are under 70 and a never smoker. But don’t worry: the association

2017 The BMJ Blog

87. Richard Lehman’s journal review—6 March 2017

Richard Lehman’s journal review—6 March 2017 Richard Lehman's journal review—6 March 2017 - The BMJ ---> Richard Lehman reviews the latest research in the leading medical journals. NEJM 2 Mar 2017 Vol 376 “Subclinical hypothyroidism” in pregnancy Observational studies have shown an association between high levels of thyroid stimulating hormone (TSH, or thyrotropin) or low levels of free thyroxine (T4) or both in mothers and lowered measures of intelligence in their children. As so often happens (...) Here’s an observational study comparing 1746 patients who developed type 1 diabetes before the age of 20 with 272 who had type 2 diabetes, also with onset before 20. The prevalence of diabetic kidney disease, retinopathy, and peripheral neuropathy was significantly greater in patients with type 2 diabetes, even after adjustment for differences in hemoglobin A 1c , body mass index, waist-height ratio, and mean arterial blood pressure. This is very worrying. One could quibble about the adjustments

2017 The BMJ Blog

88. Guidelines on the initial assessment, management outside specialised centres and referral pathways for patients with Graves' orbitopathy

radioiodine is used. Measure thyroid function every 1–2 months for the ? rst 6 months beginning no later than 4 weeks post-radioiodine. Introduce thyroxine when free T4 levels are low or showing a downward trend within the normal reference range, even in the absence of a raised TSH, as the rise in TSH may be delayed. ix. Patients with inactive GO can be treated with radioiodine without steroid cover, provided hypothyroidism is avoided (2+, C). Guidance for general ophthalmologists General (...) and identify those who may bene? t from referral to specialised centres. Recommendations Levels of evidence were graded according to SIGN 50. 6 These are indicated in each case where the evidence base is stronger than guideline development group experience and opinion alone. Particular good practice points are emphasised thus . Relevant supplementary source data (S1-5) are referred to and available online at http://www.btf-thyroid.org/index. php/campaigns/teamed (S1, common associated symptoms and signs

2015 British Thyroid Association

89. The Agenda for Familial Hypercholesterolemia (PubMed)

The Agenda for Familial Hypercholesterolemia The Agenda for Familial Hypercholesterolemia | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump (...) to Free Access article The Agenda for Familial Hypercholesterolemia A Scientific Statement From the American Heart Association , MD, FAHA, Chair , RN, MSN, FAHA , MD, MPH , PhD , PharmD , MD, PhD, FAHA , MD, MPH, FAHA , MD, PhD , MD, FAHA , MD, PhD , MD, PhD, FAHA , and DSc, MD, PhD MD, PhD, FAHAon behalf of the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing

Full Text available with Trip Pro

2015 American Heart Association

90. State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization

State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization | Circulation Research Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 February 2019 February 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access (...) and sprouting assays Very reproducibleAllows the study of EC tube formation and sprouting in physiologically relevant 3D matrix environmentsCan be reproducibly performed under serum-free conditions with defined recombinant growth factorsCan be performed with various human ECs (eg, HUVECs) that can be genetically manipulatedEC tubes that are formed can be subjected to flow forces EC only conditions without mural cellsThus far, isolated rodent ECs have not worked well in these assay modelsVariable growth

Full Text available with Trip Pro

2015 American Heart Association

91. Avelumab (Bavencio) - Neuroendocrine Tumors

CPP critical process parameter CR complete response CT computed tomography Ctrough concentration at the end of the dosing interval DDI drug-drug interaction DMRIE 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxy ethyl ammonium bromide (transfection reagent) DOR duration of response DP drug product DRR durable response rate DS drug substance ECG electrocardiogram ECOG Eastern Cooperative Oncology Group FT4 free thyroxine HCP host cell proteins HIV human immunodeficiency virus HMW high molecular weight (...) metastatic Merkel cell carcinoma NAb neutralizing antibody NCA non-compartmental analysis NK natural killer NSCLC non-small cell lung cancer ORR objective response rate OS overall survival PBMC peripheral blood mononuclear cell PD-1 programmed death 1 PD-L1 programmed death ligand 1 PFS progression-free survival PK pharmacokinetic(s) Pop PK population pharmacokinetic(s) PR partial response QTc QT interval corrected for heart rate QTcF QT interval corrected for heart rate by Fridericia’s formula QTcP QT

2017 European Medicines Agency - EPARs

92. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

-stimulatedTgafter surgery and 131 I identi?es patients with a high probability of being disease-free (286,287,298–300). Therefore, an unde- tectable TSH-stimulated Tg in children is similarly consid- eredtobeanindicatorofdiseaseremission,althoughamildly positive stimulated Tg ( 2ng/mL but 10ng/mL) warrant further evaluation to localize disease and inform the decision as to whether addi- tional surgery and/or 131 I therapy would be bene?cial or whether one should pursue continued observation. Recommendation

2015 Pediatric Endocrine Society

93. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

, laboratory pro- cess quality assurance score (for multiple relevant domains) was associated with the presence of CLIA certi?cation (188). In a large, international survey of medical genetic testing labo- ratory directors, accreditation of the laboratory was associated with a higher quality assurance index score (189). [A17] AUS/FLUS cytology & RECOMMENDATION 15 (A) For nodules with AUS/FLUS cytology, after consider- ation of worrisome clinical and sonographic features, in- vestigations such as repeat FNA

2015 Pediatric Endocrine Society

94. Management of Thyroid Cancer

Differentiated thyroid cancer* EBRT External beam radiotherapy EORTC European Organisation for Research and Treatment of Cancer ETA European Thyroid Association FACS Fluorescent activated cell sorter FNMTC Familial non-medullary thyroid cancer FDG Fluoro-deoxy-glucose FKGL Flesch-Kincaid Grade Level FMTC Familial medullary thyroid cancer FNAB Fine-needle aspiration biopsy FNAC Fine-needle aspiration cytology FRAX Fracture Risk Assessment Tool FTC Follicular thyroid cancer* FT4 free thyroxine FVPTC follicular

2014 British Thyroid Association

95. Genetic testing for hereditary mutations in the RET gene

susceptibility to MEN2. RET mutation testing is a part of the current clinical pathway. It was compared with a hypothetical algorithm that included a mix of historical treatment and current tests (other than the RET test), which outlines the approach to the diagnosis, surveillance and management of suspected MEN2 in a setting without genetic testing. Two clinical management algorithms were provided for RET mutation testing in index cases with an MTC and without an MTC, and for their close family members (...) of MTC or phaeochromocytoma in a close relative) who are found not to have an MTC would be assumed not to have MEN2. Therefore, the index case and their family members would not 4/18 be screened or undergo surveillance. However, in the current setting where genetic testing is available, patients with this clinical profile who have a RET mutation would be diagnosed with MEN2 and therefore undergo prophylactic total thyroidectomy and lifelong surveillance. Their family members would also undergo

2013 Medical Services Advisory Committee

96. Thyroid Function in Patients With a Fontan Circulation. (PubMed)

function (3.1 ± 0.1 vs 3.5 ± 0.1 pg/dl, p <0.01). The free triiodothyronine level was significantly and negatively correlated with the relaxation time constant (p = 0.03) and brain natriuretic hormone (p <0.01) level and positively correlated with the cardiac index (p = 0.04). In conclusion, venous congestion in Fontan patients may cause thyroid dysfunction, which can be responsible for decreased ventricular function and cardiac output in Fontan patients. Thus, thyroid function should be routinely (...) Thyroid Function in Patients With a Fontan Circulation. In this study, we tested our hypothesis that thyroid function is impaired and contributes to perturbed hemodynamics in patients after Fontan operation. Cardiac catheterization and blood tests for thyroid function were performed in 37 patients who underwent a Fontan operation. Among them, 12 patients (33%) had subclinical thyroid dysfunction with an elevated thyroid-stimulating hormone level despite normal thyroxine levels. Thyroid

2018 American Journal of Cardiology

97. GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Baseline in thyroxine stimulating hormone (TSH)-Part 1 [ Time Frame: Baseline and up to 2 years ] Blood samples will be collected to assess change from Baseline in TSH. Change from Baseline in free triiodothyronine (T3)-Part 1 [ Time Frame: Baseline and up to 2 years ] Blood samples will be collected to assess change from Baseline in free T3. Change from Baseline in free thyroxine (T4)-Part 1 [ Time Frame: Baseline and up to 2 years ] Blood samples will be collected to assess change from Baseline (...) in free T4. Overall survival-Part 2 [ Time Frame: Up to 4 years ] For subjects in Part 2, overall survival is defined as time from the date of randomization to the date of death due to any cause. Secondary Outcome Measures : Overall response rate-Part 1 [ Time Frame: Up to 4 years ] Overall response rate is defined as percentage of subjects with confirmed complete response or partial response at any time as per response evaluation criteria in solid tumors (RECIST) version 1.1. Overall response rate

2018 Clinical Trials

98. Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer

, the microbiome and immune regulation, gut, vaginal and uterine microbiota profiles will be characterized and potential associations with body mass index (BMI), pre-treatment TIL numbers, clonality of TILs and change in the number and phenotype of TILs will be investigated. Secondary clinical objectives include (1) of the pathologic response rate after one cycle of pembrolizumab following hysterectomy and surgical staging in stage I/II, serous/clear cell EC and stage III, G3 (serous, clear cell (...) of Immune and Obesity/Inflammation EC Signatures with TILs [ Time Frame: 3 weeks ] Compare possible associations of immune and obesity/inflammation EC signatures with (1) Body Mass Index (BMI) (2) pre-treatment TIL numbers (3) clonality of TILs and (4) change in number and phenotype of TILs. Correlation of Microbiota Profiles with TILs [ Time Frame: 3 weeks ] Compare possible associations of gut, vaginal and uterine microbiota profiles with (1) BMI (2) pre-treatment TIL numbers (3) clonality of TILs

2018 Clinical Trials

99. Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

: Progression-free survival [ Time Frame: 60 months ] Progression-free survival (PFS), as defined as the time between treatment initiation and disease progression or patient death from any cause, whichever came first Secondary Outcome Measures : Grade 3/4 adverse events (AEs) [ Time Frame: 60 months ] Incidence (%) Grade 3/4 adverse events (AEs) Treatment-related adverse events [ Time Frame: 60 months ] Incidence (%) of treatment-related adverse events Patient compliance to the experimental treatment [ Time (...) treatment on plasma fatty acids, measured through mass spectrometry analysis Effect of the experimental treatment on urinary ketones [ Time Frame: 40 months ] Effect of the experimental treatment on the concentration of urinary ketones Impact of plasma glucose modifications on progression free survival [ Time Frame: 40 months ] Impact of plasma glucose modifications during the treatment on progression free survival Impact of serum insulin modifications on progression free survival [ Time Frame: 40

2018 Clinical Trials

100. Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

-Hodgkin Lymphoma Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Drug: Etoposide Biological: Nivolumab Drug: Prednisone Biological: Rituximab Drug: Vincristine Sulfate Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To determine 2-year progression-free survival (PFS) of nivolumab in combination with DA-REPOCH with short course nivolumab maintenance. SECONDARY OBJECTIVES: I. To determine the objective response rate (ORR), complete response (CR) rate, and duration of response to nivolumab (...) tumor and microenvironment expression of PD-L1 and microenvironment expression of PD-1 with PFS. III. To correlate cell of origin, MYC and Bcl-2 expression, Epstein-Barr virus (EBV)-positivity, and Ki67 proliferation index with response to treatment. IV. To determine the effect of nivolumab in combination with DA-REPOCH on immune cell subsets in the peripheral blood over time. V. To correlate circulating tumor (ct) deoxyribonucleic acid (DNA) with disease response by positron emission tomography

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>